Soleno Therapeutics Inc (SLNO)
42.80
-2.20
(-4.88%)
USD |
NASDAQ |
May 13, 13:44
Soleno Therapeutics Enterprise Value: 1.291B for May 10, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 10, 2024 | 1.291B |
| May 09, 2024 | 1.377B |
| May 08, 2024 | 1.332B |
| May 07, 2024 | 1.349B |
| May 06, 2024 | 1.322B |
| May 03, 2024 | 1.295B |
| May 02, 2024 | 1.428B |
| May 01, 2024 | 1.373B |
| April 30, 2024 | 1.280B |
| April 29, 2024 | 1.308B |
| April 26, 2024 | 1.060B |
| April 25, 2024 | 1.042B |
| April 24, 2024 | 1.107B |
| April 23, 2024 | 1.133B |
| April 22, 2024 | 1.049B |
| April 19, 2024 | 1.048B |
| April 18, 2024 | 1.036B |
| April 17, 2024 | 1.061B |
| April 16, 2024 | 1.057B |
| April 15, 2024 | 1.081B |
| April 12, 2024 | 1.036B |
| April 11, 2024 | 1.096B |
| April 10, 2024 | 1.068B |
| April 09, 2024 | 1.164B |
| April 08, 2024 | 1.139B |
| Date | Value |
|---|---|
| April 05, 2024 | 1.187B |
| April 04, 2024 | 1.171B |
| April 03, 2024 | 1.186B |
| April 02, 2024 | 1.187B |
| April 01, 2024 | 1.177B |
| March 28, 2024 | 1.220B |
| March 27, 2024 | 1.221B |
| March 26, 2024 | 1.233B |
| March 25, 2024 | 1.183B |
| March 22, 2024 | 1.194B |
| March 21, 2024 | 1.237B |
| March 20, 2024 | 1.259B |
| March 19, 2024 | 1.248B |
| March 18, 2024 | 1.229B |
| March 15, 2024 | 1.241B |
| March 14, 2024 | 1.198B |
| March 13, 2024 | 1.258B |
| March 12, 2024 | 1.254B |
| March 11, 2024 | 1.262B |
| March 08, 2024 | 1.287B |
| March 07, 2024 | 1.289B |
| March 06, 2024 | 1.336B |
| March 05, 2024 | 1.304B |
| March 04, 2024 | 1.364B |
| March 01, 2024 | 1.427B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-12.47M
Minimum
Dec 15 2022
1.489B
Maximum
Feb 27 2024
171.70M
Average
45.37M
Median
Oct 04 2019
Enterprise Value Benchmarks
| Avid Bioservices Inc | 661.08M |
| Creative Medical Technology Holdings Inc | -4.086M |
| Viking Therapeutics Inc | 7.157B |
| Avenue Therapeutics Inc | 1.052M |
| Mind Medicine Inc | 427.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.30M |
| Total Expenses (Quarterly) | 12.83M |
| EPS Diluted (Quarterly) | -0.3566 |
| Earnings Yield | -7.00% |
| Normalized Earnings Yield | -161.75 |